AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (847)	10/11/1997 11:52:00 PM
From: D.Right	of 2173

Dear Henry: Misread is O.K. We all make mistakes sometimes as long as it is not a bad rumor. However, I think the news you quoted was old news. The company had a news release on Aug. 4, 1997. In it, they made the statement that for Rezulin-insulin combination patients was 1.3 percentage points (reduction of HbA1c) compared to insulin alone. I don't know how to make the link on SI yet, but the site is: biz.yahoo.com I hope you stop calling a 0.5% to 1% reduction in HbA1c "IFFY" now. If 1% is iffy, then 1.3% is very close to iffy as well. We know Rezulin is a great drug. AMLN will be very proud to have its pramlintide in the same category. Have some sleep. D.Right

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next